Cellules souches

<p>Sonidegib diphosphate (LDE225 diphosphate) is a selective antagonist of Smo that inhibits murine Smo and human Smo.Cost-effective and quality-assured.</p>

<p>CCT251545 is an potent and oral-bioavailable WNT signaling inhibitor(IC50 of 5 nM in 7dF3 cells).</p>

<p>NGP555 is a modulator of γ-secretase.</p>

<p>CWP232228 is a selective Wnt/β-catenin pathway inhibitor targeting β-catenin/TCF binding, halting breast/liver CSC growth and metastasis safely.</p>

<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>

<p>ROCK inhibitor-2 is a selective dual inhibitor of ROCK1 and ROCK2 (IC50s of 17 nM and 2 nM, respectively).</p>

<p>IK-930 is an orally active TEAD inhibitor (EC50 &lt; 0.1 µM) with potent potency.</p>

<p>Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.</p>

<p>Netarsudil Dihydrochloride (AR-13324 Dihydrochloride) is an inhibitor of Rho-related protein kinase (ROCK) and norepinephrine transporter (NET) and is effective in reducing intraocular pressure (IOP).Cost-effective and quality-assured.</p>

<p>Cyanoacetohydrazide (Cyanoacetic hydrazide) is an anti-TB drug. It has also been used to derive compounds that may have antitumor properties.</p>

<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>

<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: &gt;14.7, &gt;30 μM).</p>

<p>Ponsegromab (PF 06946860), a humanized anti-GDF15 antibody, may treat cancer cachexia by blocking GDF15/GFRAL signaling.</p>

<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>

<p>TNIK-IN-5: strong TNIK inhibitor (IC50=0.05μM), halts Wnt signaling, effective against colorectal cancer in vitro.</p>

<p>Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.</p>

<p>E2012 is a γ-secretase modulator (GSM).</p>

<p>MRT-83 is a potent Smo antagonist.</p>

<p>Silmitasertib sodium salt (CX-4945 sodium salt) is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1 nM, CK2α).</p>

<p>BRD0705: potent, selective GSK3α inhibitor, oral, IC50: 66 nM, 8x more selective than GSK3β.</p>

<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>

<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>

<p>KY1220 destabilizes both β-catenin and Ras by targeting the Wnt/β-catenin pathway. It has an IC50 of 2.1 μM in HEK293 reporter cells.</p>

<p>NMS-P715 is a highly selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).</p>

<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>

<p>JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling (IC50: 420 nM).</p>

<p>Garetosmab (REGN 2477), a human IgG4 monoclonal antibody, inhibits activin A for potential cancer treatment and FOP study.</p>

<p>BML-286 is a WNT pathway modulator with potential anticancer activity and induces β-catenin- and TCF- dependent transcriptional activity.</p>

<p>Casein kinase 1δ-IN-8 is an inhibitor of casein kinase 1δ and is used to treat neurodegenerative diseases such as Alzheimer's disease type.</p>

<p>Cirevetmab (ZTS-00521426), a caninized monoclonal antibody targeting Canis lupus familiaris TGFB1, is classified as an immunoglobulin G2-kappa.</p>

<p>MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.</p>

<p>TBCA: selective CK2 inhibitor, IC50=110 nM, Ki=77 nM, favors CK2 over CK1, DYRK1A, and 27 other kinases.</p>

<p>MSC-5046 is a selective inhibitor of TEAD1.</p>

<p>GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively</p>

<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>

<p>Super-TDU (1-31) TFA, a peptide, inhibits YAP-TEAD; it has strong anti-tumor effects in gastric cancer models.</p>

<p>F7H is an FZD7 antagonist, a potent ligand for the FZD7 transmembrane domain (TMD), with potential antitumor and bacteriostatic activities.</p>

<p>β-catenin modulator IIa-661 is a small molecule inhibitor of the Wnt pathway with antitumour activity.</p>

<p>GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.</p>

<p>GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.</p>

<p>ALK5-IN-83 (compound 13b) is an ALK5 inhibitor with an IC50 of 0.13 μM. It suppresses TGF-β1-induced Smad2 phosphorylation and cell motility in A549 cells.</p>

<p>Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.</p>

<p>CK1δ-IN-6: potent, selective CK-1δ inhibitor, IC50 23 nM, neuroprotective, anti-inflammatory, for neurodegenerative research.</p>

<p>Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.</p>

<p>P17 Peptide, a human TGF-β1 inhibitory peptide, effectively blocks the activity of woodchuck TGF-β1.</p>

<p>Linavonkibart (SRK181) is a humanized antibody targeting TGFβ1 that blocks the release of TGF-β1 protein by specifically binding latent TGF-β1.</p>

<p>PROTAC YAP degrader-1, a targeted proteolysis promoting chimeric molecule, both degrades the YAP protein and inhibits its nuclear localization. This compound is formulated with Demethyl-NSC682769 as the target protein ligand, and utilizes (R,S,R)-AHPC-PEG2-C2-boc, which is the E3 ubiquitin ligase ligand + Linker conjugate. The linker incorporated in the design is Acid-PEG2-C2-Boc.</p>

<p>Foxy-5 Ammonium Salt, a WNT5A mimetic, blocks epithelial cancer cell migration without β-catenin impact and curbs prostate cancer spread.</p>

<p>Carboxylesterase-IN-2 is a potent Carboxylesterase Notum inhibitor (IC50 &lt;= 10 nM).Carboxylesterase-IN-2 has potential for the study of cancer diseases.</p>

<p>BAY 593 functions as an inhibitor of geranylgeranyltransferase-I (GGTase-I), effectively preventing the activation of Rho-GTPases and consequently inactivating YAP1/TAZ signaling pathways. It has been shown to inhibit tumor growth dose-dependently in xenograft mouse models, exhibiting IC50 values of 38.4 nM in MT-1080 cells and 564 nM in MDA-MB-231 cells, as well as in PXF 541 xenografts.</p>

<p>Wnt pathway inhibitor 3 is a potent AC1 inhibitor with an IC50 value of 45 nM.Wnt pathway inhibitor 3 has antiproliferative activity and can be used in studies</p>

<p>STAT3-IN-37 (Compound 101) is an inhibitor of STAT3, with an IC50 of 15 nM as measured by DNA-HTRF assay and 2 nM as determined through human whole blood SOCS3 qPCR assay.</p>

<p>LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1/2, ROCK, PKA, and can be used to study glaucoma.</p>

<p>2H-1-Benzopyran-3-carboxamide, N-[4-(4-ethyl-1-piperazinyl)phenyl]-2-oxo- is a compound that is potential for the treatment of tumours.</p>

<p>BMS-906024 (Osugacestat) is a gamma secretase inhibitor, a Notch inhibitor.BMS-906024 has broad-spectrum antitumour activity.</p>

<p>STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.</p>

<p>Wnt/β-catenin agonist 3 is a Wnt/beta-catenin agonist.</p>

<p>Plant 14-3-3-IN-1 (Compound 2) is an inhibitor of the Arabidopsis thaliana 14-3-3 protein, with an IC50 of 1.21 μM. It exhibits varying inhibitory activity against different 14-3-3 isoforms and promotes the closure of leaf stomata.</p>

<p>DC-TEADin02 is an inhibitor of TEAD auto palmitoylation (IC50 = 197 nM). DC-TEADin02 can be in studies about development, regeneration, and tissue homeostasis.</p>

<p>Lerdelimumab (CAT-152) is an IgG4 monoclonal antibody targeting TGF-β2, used in glaucoma scarring research.</p>

<p>TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, showing inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% for TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at 10 μM. It exhibits strong antiproliferative and antimigratory effects on prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds potential for research in the field of cancer therapeutics.</p>

<p>Casein kinase 1δ-IN-7 is a Casein kinase 1δ inhibitor for neurodegenerative diseases such as Alzheimer's disease.</p>

<p>CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.</p>

<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>

<p>pan-TEAD-IN-1 (Compound 3) is an orally active pan-inhibitor of TEAD, disrupting its interaction with coactivators YAP/TAZ by targeting the palmitoylation site of TEAD. This inhibition leads to the downregulation of oncogene transcription, such as Ctgf and Cyr61, within the Hippo signaling pathway. Demonstrating outstanding efficacy, pan-TEAD-IN-1 has an IC50 of 0.36 nM for luciferase and 1.52 nM for H226 cells, along with favorable pharmacokinetic properties (AUC0–∞= 228.7 μg/mL·min, T1/2= 183.9 min). The compound significantly inhibits tumor growth in xenograft models of TEAD-dependent cancers, indicating its potential for research in these cancer types.</p>

<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>

<p>CK2-IN-14 (Compound 10b) is an inhibitor of cyclin-dependent kinase 2α with an IC50 of 36.7 nM. It effectively hinders the growth of cancer cell lines 786-O and U937, with GI50 values of 7.3 μM and 7.5 μM, respectively.</p>

<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>

<p>STAT3-IN-39 (compound 10K) is an orally active inhibitor of STAT3, demonstrating effective inhibition of STAT3 phosphorylation with an IC50 of 0.47 μM in NIH-3T3 cells. It hinders TGF-β1-induced fibrotic responses and prevents epithelial-mesenchymal transition in A549 cells. STAT3-IN-39 is applicable for research related to idiopathic pulmonary fibrosis.</p>

<p>Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and is an effective Wnt agonist.</p>

<p>Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.</p>

<p>GSK-3β inhibitor 14 (1,5-Benzothiazepin-4(5H)-one, 2,3-dihydro-2-methyl-5-(phenylmethyl)-) is a weak GSK-3β inhibitor, IC50﹥ 100μM.</p>

<p>APTSTAT3-9R acetate is a selective peptide binding STAT3 with antiproliferative and antitumor activity.</p>

<p>HC-258 is a direct TEAD inhibitor covalent Cys380, and reduces the transcriptional levels and inhibits the migration of CTGF, CYR61, AXL and NF2 MDA-MB-231.</p>

<p>Foxy-5 acetate: Wnt 5A agonist, inhibits cancer cell migration/invasion, boosts calcium signaling, doesn't activate β-catenin.</p>

<p>VT104 is a potent and orally active YAP/TAZ inhibitor for cancer research.Cost-effective and quality-assured.</p>

<p>WAY-296817 inhibits CK1, potential for circadian rhythm and inflammation research.</p>

<p>GSK3β inhibitor II is a GSK3β inhibitor. GSK3β inhibitor II exhibits the research potential of Alzheimer's disease (AD).</p>

<p>Emugrobart is a humanized IgG1κ antibody targeted at GDF8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>

<p>YAP/TEAD-IN-1 (compound 4) is a potent inhibitor of YAP and TEAD, exhibiting antioxidant properties. It demonstrates antiproliferative effects on tumor cells while showing minimal cytotoxic activity towards normal human cells.</p>

<p>GSK-3β inhibitor22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM, showing potential for Alzheimer's disease research.</p>

<p>Ac-GpYLPQTV-NH2 acetate is a STAT3 inhibitor with an IC50 value of 0.33 μM. It also exhibits antitumor properties.</p>

<p>STAT3HiBiT degrader 1 is a potent degrader of STAT3HiBiT, exhibiting a DC50 of less than 0.05 μM in A549 cells.</p>

<p>GKI-1 HCl is a Greatwall (GWL) kinase inhibitor that inhibits hGWLFL and hGWL-KinDom.The inhibitory effect of GKI-1 HCl on ROCK1 is more significant.</p>

<p>YAP/TAZ Inhibitor-4 (Compound 45) acts as an inhibitor of YAP/TAZ, exhibiting inhibitory activity on TEAD transcriptional activation by preventing the interaction between YAP or TAZ and TEAD.</p>

<p>GSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.</p>

<p>ABC99 irreversibly inhibits wnt-deacylating enzyme NOTUM (IC50: 13 nM) with high serine hydrolase family selectivity.</p>

<p>Akt/ROCK-IN-1 (B12) is a dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively.</p>

<p>Tubastatin inhibits TGF-β1-induced S6K phosphorylation, HIF-1α expression and VEG F expression.</p>

<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>

<p>CSNK2-IN-2 (compound 2) is an orally active inhibitor of CSNK2. It is utilized in antiviral research.</p>

<p>WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of &gt; 33 μM.</p>

<p>Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new</p>

<p>WAY-656935 inhibits ROCK.</p>

<p>MSC-1254 is a reversible, selective, and covalent inhibitor of TEAD1, primarily utilized in cancer research.</p>

<p>STAT3-IN-34 (Compound 15E) acts as a STAT3 inhibitor, blocking both the nuclear translocation and the transcriptional regulator activity of STAT3. It effectively inhibits HaCaT cell proliferation with an IC50 value of 0.008 μM. Additionally, STAT3-IN-34 reduces IL-17A expression and mitigates Imiquimod-induced psoriasis in mouse models.</p>

<p>Rilogrotug is a humanized IgG1κ monoclonal antibody targeting GDF15, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.</p>

<p>LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a TGF-尾1 antagonist that inhibits TSP-1 binding to LAP and reduces renal interstitial fibrosis and liver fibrosis.</p>

<p>CCT 031374 hydrobromide is a TCF/β-catenin inhibitor with antitumor activities.</p>

<p>YAP-TEAD-IN-1 acetate is an effective and competitive inhibitor of YAP–TEAD interaction with an IC50 of 25 nM.</p>

<p>SLLK is a control peptide for LSKL.</p>

<p>Ac-ESMD-CHO functions as an inhibitor of both caspase-3 and caspase-7, specifically obstructing the proteolytic cleavage of the caspase-3 precursor peptide (</p>

<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>

<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>

<p>YAP-TEAD-IN-3 inhibitor YAP/TAZ-TEAD interactions Avi-human TEAD (4217-434) YAP-TEAD-IN-3 inhibits YAP reporter gene expression and NCI-H2052 cell proliferation</p>